Simultaneous knockdown of uPA and MMP9 can reduce breast cancer progression by increasing cell-cell adhesion and modulating EMT genes.

PubWeight™: 0.81‹?›

🔗 View Article (PMID 26906973)

Published in Sci Rep on February 24, 2016

Authors

Anuradha Moirangthem1, Banashree Bondhopadhyay1, Mala Mukherjee2, Arghya Bandyopadhyay2, Narendranath Mukherjee3, Karabi Konar2, Shubham Bhattacharya2, Anupam Basu1

Author Affiliations

1: Molecular Biology and Human Genetics Laboratory, Department of Zoology, The University of Burdwan, Golapbag, Burdwan 713104, West Bengal, India.
2: Department of Pathology, Burdwan Medical College and Hospital, BurdwanWest Bengal 713104, India.
3: Department of Surgery, Burdwan Medical College and Hospital, BurdwanWest Bengal 713104, India.

Articles cited by this

Challenges in circulating tumour cell research. Nat Rev Cancer (2014) 2.81

Metastasis mechanisms. Biochim Biophys Acta (2009) 2.51

RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem (2005) 2.38

Wound-healing assay. Methods Mol Biol (2005) 2.28

The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev (2003) 2.22

EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol (2012) 2.22

Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis (2008) 1.69

Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem (2009) 1.44

Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol (2004) 1.35

Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther (2005) 1.33

uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem (2008) 1.25

Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int J Oncol (2006) 1.24

RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer (2007) 1.23

Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget (2014) 1.20

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost (2004) 1.17

6-Shogaol, an active constituent of ginger, inhibits breast cancer cell invasion by reducing matrix metalloproteinase-9 expression via blockade of nuclear factor-κB activation. Br J Pharmacol (2010) 1.11

Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res (2014) 1.09

Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells. Int J Oncol (2010) 1.04

Oct4 mediates tumor initiating properties in oral squamous cell carcinomas through the regulation of epithelial-mesenchymal transition. PLoS One (2014) 1.00

Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysis. Asian Pac J Cancer Prev (2013) 0.95

Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-kappa B activity leading to apoptosis in breast tumors. Clin Cancer Res (2008) 0.95

Plasminogen activator inhibitor-1 (PAI-1) facilitates retinal angiogenesis in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci (2009) 0.94

High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis. World J Gastroenterol (2012) 0.93

Vimentin expression in benign and malignant breast epithelium. J Clin Pathol (1993) 0.89

The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective. Curr Pharm Des (2003) 0.82

Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer. BMC Cancer (2015) 0.82

Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator. Cancer Invest (2010) 0.81